This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lania, A. Articles by Spada, A. Search for Related Content PubMed PubMed Citation Articles by Lania, A. Articles by Spada, A.

Constitutively Active Gs Is Associated with an Increased Phosphodiesterase Activity in Human Growth Hormone-Secreting Adenomas¹

Institute of Endocrine Sciences, Ospedale Maggiore IRCCS (A.L., E.B., S.M., A.S.), Italian Auxological Institute IRCCS (L.P.), and Department of Neurosurgery, Scientific Institute San Raffaele (M.L.), University of Milan, 20122 Milan, Italy

Address all correspondence and requests for reprints to: Anna Spada, M.D., Istituto di Scienze Endocrine Ospedale Maggiore, IRCCS, via Francesco Sforza 35, 20122 Milano, Italy. E-mail: endosci{at}imiucca

Because phosphodiesterase (PDE) expression and activity are controlled by cAMP, we investigated whether activating mutations of Gs gene that occur in human GH-secreting adenomas are associated with increased PDE activity. We studied 10 adenomas with wild-type Gs (gsp-) and 8 with mutant Gs (gsp+). Although, in the absence of PDE inhibitors, intracellular cAMP levels were similar in gsp+ e gsp- adenomas, the PDE blockade with 3-isobutyl-1-methylxanthine induced a marked increase in cAMP in all but one gsp+ adenoma (% increase: from 77 to 2900) and a slight rise in only 2 gsp-. Similar results were obtained with the PDE4 selective inhibitor 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone. In vitro GH release was significantly higher in gsp+ than in gsp- adenomas (315 ± 158 vs. 82 ± 53 µg/well; P < 0.01), and PDE blockade caused a further increase in 3 of 5 gsp+ adenomas but not in gsp- tumors. By direct measurement, PDE activity was about 7-fold higher in gsp+ than in gsp- adenomas (320 ± 213 vs. 48 ± 23 pmol/min·mg protein; P < 0.05) and was largely 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone sensitive. This study first demonstrates that activating mutations of the Gs gene that naturally occur in pituitary adenomas is associated with an increased PDE activity that might, at least partially, counteract the constitutive activation of the cAMP-dependent pathway.

This article has been cited by other articles:

				D. Romano, K. Magalon, M. Pertuit, R. Rasolonjanahary, A. Barlier, A. Enjalbert, and C. Gerard Conditional Overexpression of the Wild-Type Gs{alpha} as the gsp Oncogene Initiates Chronic Extracellularly Regulated Kinase 1/2 Activation and Hormone Hypersecretion in Pituitary Cell Lines Endocrinology, June 1, 2007; 148(6): 2973 - 2983. [Abstract] [Full Text] [PDF]

				G. Mantovani, S. Bondioni, S. Ferrero, B. Gamba, E. Ferrante, E. Peverelli, S. Corbetta, M. Locatelli, P. Rampini, P. Beck-Peccoz, et al. Effect of Cyclic Adenosine 3',5'-Monophosphate/Protein Kinase A Pathway on Markers of Cell Proliferation in Nonfunctioning Pituitary Adenomas J. Clin. Endocrinol. Metab., December 1, 2005; 90(12): 6721 - 6724. [Abstract] [Full Text] [PDF]

				P. Luciani, S. Gelmini, E. Ferrante, A. Lania, S. Benvenuti, S. Baglioni, G. Mantovani, I. Cellai, F. Ammannati, A. Spada, et al. Expression of the Antiapoptotic Gene Seladin-1 and Octreotide-Induced Apoptosis in Growth Hormone-Secreting and Nonfunctioning Pituitary Adenomas J. Clin. Endocrinol. Metab., November 1, 2005; 90(11): 6156 - 6161. [Abstract] [Full Text] [PDF]

				A. Lania, G. Mantovani, and A. Spada Genetics of Pituitary Tumors: Focus on G-Protein Mutations Experimental Biology and Medicine, October 1, 2003; 228(9): 1004 - 1017. [Abstract] [Full Text] [PDF]

				A. Lania, M. Filopanti, S. Corbetta, M. Losa, E. Ballare, P. Beck-Peccoz, and A. Spada Effects of Hypothalamic Neuropeptides on Extracellular Signal-Regulated Kinase (ERK1 and ERK2) Cascade in Human Tumoral Pituitary Cells J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1692 - 1696. [Abstract] [Full Text] [PDF]

				H. Shinozaki, V. Butnev, Y.-X. Tao, K. L. Ang, M. Conti, and D. L. Segaloff Desensitization of Gs-Coupled Receptor Signaling by Constitutively Active Mutants of the Human Lutropin/Choriogonadotropin Receptor J. Clin. Endocrinol. Metab., March 1, 2003; 88(3): 1194 - 1204. [Abstract] [Full Text] [PDF]

				L. S. WEINSTEIN, M. CHEN, and J. LIU Gs{alpha} Mutations and Imprinting Defects in Human Disease Ann. N.Y. Acad. Sci., June 1, 2002; 968(1): 173 - 197. [Abstract] [Full Text] [PDF]

				L. S. Weinstein, S. Yu, D. R. Warner, and J. Liu Endocrine Manifestations of Stimulatory G Protein {alpha}-Subunit Mutations and the Role of Genomic Imprinting Endocr. Rev., October 1, 2001; 22(5): 675 - 705. [Abstract] [Full Text] [PDF]

				L. Persani, S. Borgato, A. Lania, M. Filopanti, G. Mantovani, M. Conti, and A. Spada Relevant cAMP-Specific Phosphodiesterase Isoforms in Human Pituitary: Effect of Gs{alpha} Mutations J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3795 - 3800. [Abstract] [Full Text] [PDF]

				E. Ballare, L. Persani, A. G. Lania, M. Filopanti, E. Giammona, S. Corbetta, S. Mantovani, M. Arosio, P. Beck-Peccoz, G. Faglia, et al. Mutation of Somatostatin Receptor Type 5 in an Acromegalic Patient Resistant to Somatostatin Analog Treatment J. Clin. Endocrinol. Metab., August 1, 2001; 86(8): 3809 - 3814. [Abstract] [Full Text] [PDF]

				A. Peri, B. Conforti, S. Baglioni-Peri, P. Luciani, F. Cioppi, L. Buci, S. Corbetta, E. Ballaré, M. Serio, and A. Spada Expression of Cyclic Adenosine 3',5'-Monophosphate (cAMP)-Responsive Element Binding Protein and Inducible-cAMP Early Repressor Genes in Growth Hormone-Secreting Pituitary Adenomas with or without Mutations of the Gs{{alpha}} Gene J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2111 - 2117. [Abstract] [Full Text]

				M. Conti Phosphodiesterases and Cyclic Nucleotide Signaling in Endocrine Cells Mol. Endocrinol., September 1, 2000; 14(9): 1317 - 1327. [Full Text]

				L. Persani, A. Lania, L. Alberti, R. Romoli, G. Mantovani, S. Filetti, A. Spada, and M. Conti Induction of Specific Phosphodiesterase Isoforms by Constitutive Activation of the cAMP Pathway in Autonomous Thyroid Adenomas J. Clin. Endocrinol. Metab., August 1, 2000; 85(8): 2872 - 2878. [Abstract] [Full Text]

				A. Barlier, I. Pellegrini-Bouiller, G. Gunz, A. J. Zamora, P. Jaquet, and A. Enjalbert Impact of gsp Oncogene on the Expression of Genes Coding for Gs{alpha}, Pit-1, Gi2{alpha}, and Somatostatin Receptor 2 in Human Somatotroph Adenomas: Involvement in Octreotide Sensitivity J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2759 - 2765. [Abstract] [Full Text]

				R. Romoli, A. Lania, G. Mantovani, S. Corbetta, L. Persani, and A. Spada Expression of Calcium-Sensing Receptor and Characterization of Intracellular Signaling in Human Pituitary Adenomas J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2848 - 2853. [Abstract] [Full Text]

				E. Ballaré, S. Mantovani, A. Lania, A. M. Di Blasio, L. Vallar, and A. Spada Activating Mutations of the Gs{alpha} Gene Are Associated with Low Levels of Gs{alpha} Protein in Growth Hormone-Secreting Tumors J. Clin. Endocrinol. Metab., December 1, 1998; 83(12): 4386 - 4390. [Abstract] [Full Text]